fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
SurfKY News
Information provided by the United States Food and Drug Administration

e-max.it: your social media marketing partner

LIKE SurfKY on Facebook - Click here to LIKE us now.

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

Stock Report Sponsored by

In Other News...

Owensboro Human Relations Commission Board Meeting Today

OWENSBORO, Ky. (10/13/15) — The OWensboro Human Relations Commission regualr meeting will take place at 5 p.m.… Read More

Owensboro Traffic Advisory

OWENSBORO, Ky. (10/12/15) — A contractor for the Kentucky Transportation Cabinet plans nighttime lane restrictions… Read More

Most Read This Week

October 10, 2015 6729

25-Mile Car Chase on Pennyrile Ends in Two Arrests

by SurfKY News
October 07, 2015 5136

Alleged Attempt to Hide Meth in Doughnuts Results…

by SurfKY News
October 07, 2015 3481

3 From Greenville Indicted On Drug Charges

by SurfKY News
October 07, 2015 3450

Vehicle Overturns during Two-Car Collision

by Rita Dukes Smith, SurfKY News Director
October 12, 2015 3210

Crime Stoppers Top Most Wanted - October 12, 2015

by SurfKY News

Most Read This Month

September 16, 2015 13969

Mining Accident Fatality - Update

by Doreen Dennis, SurfKY News
September 30, 2015 12042

Dawson Woman Dead After Princeton Factory…

by SurfKY News

Stories Trending Now

October 12, 2015 3210

Crime Stoppers Top Most Wanted - October 12, 2015

by SurfKY News
October 12, 2015 2083

Two-Vehicle Collision Results in One Driver…

by SurfKY News
October 12, 2015 2047

MPD Foot Patrol Charges Man with Trafficking in…

by SurfKY News
October 12, 2015 2024

Four Injured after Vehicle Careens down…

by SurfKY News
October 12, 2015 1529

Kentucky Health Co-op Closing Due to Congress…

by SurfKY News
October 12, 2015 1443

Driver Dies after Single-Vehicle Collision on…

by SurfKY News
October 12, 2015 1270

UPDATE: KSP Captures Escapee

by SurfKY News
October 13, 2015 1222

BBQ Champs Chosen during Hanson Lions Blast-off

by Tammy Holloway, SurfKY News
October 12, 2015 1112

Madisonville Police Arrest Reports Released -…

by SurfKY News
October 13, 2015 758

UPDATE - Missing Juvenile Found

by SurfKY News